Amneal Pharmaceuticals In... (AMRX)
NYSE: AMRX
· Real-Time Price · USD
7.68
0.02 (0.26%)
At close: May 01, 2025, 2:26 PM
Amneal Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Specialty Pharma Segment Revenue | 115.64M | 105.23M | 753.89M | 96.99M | 91.68M | 102.55M | 89.48M | 97M | 85.09M | 101.01M | 92.75M | 360.44M | 312.51M | 85.47M | 87.87M | 94.26M | 985K | 97.05M |
| Amneal Specialty Pharma Segment Revenue Growth | +9.89% | -86.04% | +677.26% | +5.80% | -10.60% | +14.60% | -7.75% | +14.00% | -15.76% | +8.91% | -74.27% | +15.34% | +265.65% | -2.73% | -6.78% | +9469.14% | -98.99% | n/a |
| Generics Segment Revenue | 427.35M | 391.29M | n/a | 373.7M | 343.81M | 399.17M | 350.27M | 364.89M | 317.75M | 346.27M | 347.13M | 88.64M | 95.93M | 342.14M | 341.92M | 306.56M | n/a | 300.28M |
| Generics Segment Revenue Growth | +9.21% | n/a | n/a | +8.70% | -13.87% | +13.96% | -4.01% | +14.84% | -8.24% | -0.25% | +291.64% | -7.61% | -71.96% | +0.07% | +11.53% | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Generics Segment Revenue | 1.47B | 41.09M | 35.97M | 37.39M | 1.29B | 1.44B |
| Generics Segment Revenue Growth | +3481.36% | +14.24% | -3.81% | -97.09% | -10.68% | n/a |
| Specialty Segment Revenue | 390.46M | 374.12M | 378.32M | 355.57M | 317.53M | 223.96M |
| Specialty Segment Revenue Growth | +4.37% | -1.11% | +6.40% | +11.98% | +41.78% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 118.69M | 116.46M | 112.59M | 109M | 113.01M | 105.57M | 102.1M | 102.16M | 100.07M | 98.81M | 98.67M | 97.22M | 91.4M | 86.16M | 90.73M | 84.69M | 83.12M | 80.94M | 77.98M | 74.08M | 63.8M | 67.28M | 84.44M | 71.24M | 78.08M | 53M | 25.12M | 26.97M | 27.44M | 26.94M | 27.7M | 31.13M |
| Selling, General, and Administrative Revenue Growth | +1.91% | +3.43% | +3.30% | -3.54% | +7.04% | +3.40% | -0.06% | +2.09% | +1.28% | +0.14% | +1.48% | +6.38% | +6.08% | -5.04% | +7.13% | +1.89% | +2.69% | +3.81% | +5.25% | +16.12% | -5.18% | -20.32% | +18.53% | -8.76% | +47.30% | +110.99% | -6.84% | -1.73% | +1.86% | -2.76% | -11.00% | n/a |
| Research and Development Revenue | 61.1M | 37.1M | 39.3M | 46.56M | 42.26M | 38.62M | 40.33M | 43.27M | 51.65M | 51.57M | 53.56M | 53.02M | 50.55M | 54.23M | 51.76M | 57.16M | 46.65M | 49.12M | 37.65M | 53.02M | 40.71M | 50.53M | 58.02M | 60.53M | 47.4M | 54.38M | 48.78M | 46.23M | 48.02M | 52.11M | 39.42M | 43.51M |
| Research and Development Revenue Growth | +64.70% | -5.60% | -15.60% | +10.18% | +9.43% | -4.25% | -6.78% | -16.22% | +0.15% | -3.72% | +1.03% | +4.87% | -6.78% | +4.76% | -9.44% | +22.52% | -5.03% | +30.47% | -29.00% | +30.25% | -19.43% | -12.92% | -4.15% | +27.71% | -12.84% | +11.47% | +5.54% | -3.73% | -7.86% | +32.20% | -9.41% | n/a |